Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Lymphoma, T-Cell × zanolimumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Skin Neoplasms 2 Sezary Syndrome 2 Mycosis Fungoides 2 Lymphoma, T-Cell, Cutaneous 2 Lymphoma 2 Lymphoma, T-Cell 1

Interventions

Cyclophosphamide 10 romidepsin 9 Brentuximab Vedotin 8 Vincristine 7 Etoposide 7 Rituximab 6 Peripheral Blood Stem Cell Transplantation 6 Doxorubicin 6 fludarabine phosphate 5 fludarabine 5 Prednisone 5 Lenalidomide 5 Depsipeptides 5 Mycophenolic Acid 4 Melphalan 4 MLN 8237 4 Lactones 4 Gemcitabine 4 Whole-Body Irradiation 3 Sirolimus 3 Dexamethasone 3 Busulfan 3 Bendamustine Hydrochloride 3 Antilymphocyte Serum 3 10-propargyl-10-deazaaminopterin 3 thymoglobulin 2 tenalisib 2 pembrolizumab 2 liposomal doxorubicin 2 carfilzomib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00877656 2024-03-18

HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma

Emergent BioSolutions

Phase 2/3 Completed

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡